期刊
CANCER CELL
卷 37, 期 4, 页码 443-455出版社
CELL PRESS
DOI: 10.1016/j.ccell.2020.03.017
关键词
-
资金
- Memorial Sloan-Kettering Cancer Center (MSK) [P30 CA008748]
- Druckenmiller Center for Lung Cancer Research at MSK
- Damon Runyon Cancer Research Foundation [CI-98-18]
Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumor types, providing unprecedented survival in some patients. Despite the characteristic durability of response to ICI, unfortunately many patients with initial response will later develop acquired resistance. The current understanding of mechanisms of acquired resistance to ICIs is remarkably limited, perhaps restraining effective development of next-generation immunotherapies. Here, we examine the barriers to progress and emerging clinical reports interrogating acquired resistance with the goal to facilitate efforts to overcome acquired resistance to ICIs in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据